Xilio Therapeutics, Inc. Warrants and Rights Outstanding
Xilio Therapeutics, Inc. (XLO) had Warrants and Rights Outstanding of $30.20 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:WarrantsAndRightsOutstanding · last filed 2026-08-12
- 2026-06-30: Warrants and Rights Outstanding $30.20M.
- 2026-03-31: Warrants and Rights Outstanding $26.26M.
- 2025-12-31: Warrants and Rights Outstanding $29.56M.
- 2025-09-30: Warrants and Rights Outstanding $53.93M.
| Period end | Warrants and Rights Outstanding |
|---|---|
| 2026-06-30 | $30.20M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $26.26M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $29.56M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $53.93M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $38.55M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |